Huang, Zoufang, Chavda, Vivek P ORCID: 0000-0002-7701-8597, Vora, Lalitkumar ORCID: 0000-0001-8106-9066, Gajjar, Normi, Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771, Shah, Nirav and Chen, Zhe-Sheng ORCID: 0000-0002-8289-097X (2022) 2-deoxy-d-glucose and its derivatives for the COVID-19 treatment: an update. Frontiers in Pharmacology, 13. ISSN 1663-9812

Abstract

Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.

Search Google Scholar

Repository staff login